Aim: To investigate the usefulness of IGF-1, IGFBP3 (BP1) and IGFBP1 (BP3) as biochemical indicators to monitor nutritional status and response to Megestrol acetate (MA) Study type: Randomized, double-blind, placebo-control trial. Subjects: 27 children, age±SD; 13.89±2.69, affected of solid tumors, anorexia and weight loss. Interventions: Subjects were randomly divided into the treated group (TG) (n=15) and control group (CG) (n=12) which then received MA(5 mg/kg/day) or placebo, respectively, for 30 days. Measurements: Nutritional status was assessed by anthropometrical parameters, appetite by a categorical scale and quality of life by the Children's Play Lansky scale. IGF-I, BP1 and BP3 were measured by IRMA (DSL®). Data was determined before and after 30 days of MA treatment. Results: Statistical analysis was done using Paired t-tests and Wilcoxon's signed rank and Mann-Whitney U test In the TG, all the anthropometrical measurements, appetite and quality of life improved significantly (p<0.01) after one month of treatment. IGF-1 and BP3 increases (p<0.01). In the CG there was a significant decrease (p<0.01) in the subscapular skinfold, weight, body mass index, appetite, and quality of life. There were significant differences (p<0.01) between the CG and TG with respect to all the variables studied, except for IGBP1 (p=0.05). There was a significant correlation between weight change and BP3 (p<0.05, r=0.5, Pearson's correlation coefficient). Conclusion: MA is a powerful appetite stimulant, with subjective and objective effects on the nutritional status of children with cancer anorexia and weight loss. We propose the use of IGF-1 and BP3 as biochemical indicators to monitor nutritional status and MA response in children with cancer treated with MA.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azcona, C., De Mesa, R., Sánchez-Carpintero, R. et al. IGF-I, IGFBP1 and IGFBP3 Changes in Cancer Children Treated with Megestrol Acetate. 10. Pediatr Res 40, 516 (1996). https://doi.org/10.1203/00006450-199609000-00033
Issue Date:
DOI: https://doi.org/10.1203/00006450-199609000-00033